Sarepta Therapeutics, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $323.8 million (-12.5% year over year) and diluted EPS of -$0.27. It usually reports 12–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
324
-12.5%
|
-28
+43.7%
|
-0.27
+46.0%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
329
-35.9%
|
-5
-102.5%
|
-0.05
-102.6%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
331
-46.0%
|
331
+174.0%
|
2.88
+162.6%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
370
-42.1%
|
-412
-359.2%
|
-3.93
-362.0%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
370
-20.8%
|
-51
-250.5%
|
-0.50
-247.1%
|
|
Jul 16, 2025
16 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
513
+41.4%
|
197
+2947.9%
|
1.89
+2600.0%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
638
+74.8%
|
159
+248.4%
|
1.50
+240.4%
|
|
Jan 8, 2024
8 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SRPT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 873303
- Former names
- Sarepta Therapeutics, Inc. (until Nov 5, 2026); AVI BIOPHARMA INC (until Jul 12, 2012); ANTIVIRALS INC (until May 12, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.